457 filings
Page 8 of 23
6-K
16asdp d62214pi322fz
8 Sep 21
Current report (foreign)
7:35am
6-K
o1i6utb4
7 Sep 21
HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
6:18am
6-K
ogrm8qywofj9pfxx
2 Sep 21
Grant of Share Options under Share Option Scheme and Awards under
7:46am
6-K
qw2x5j8vo
31 Aug 21
Current report (foreign)
6:34am
6-K
enzdx2 hc7ll
26 Aug 21
Current report (foreign)
6:18am
6-K
7mi4dj2m
23 Aug 21
Current report (foreign)
6:14am
6-K
01vh3eq4x6nwbuhha
9 Aug 21
HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
6:42am
6-K
tjj79wxw0n6kbi
30 Jul 21
Current report (foreign)
6:08am
6-K
0x7re15
28 Jul 21
HUTCHMED Reports 2021 Interim Results and Provides Business Updates
8:17am
6-K
bn89ukh6e0fl1xou2 zm
28 Jul 21
Current report (foreign)
6:42am
6-K
q94cw7fk4
23 Jul 21
Current report (foreign)
8:46am
6-K
hk2bn39l60u6a 4zbh24
16 Jul 21
Current report (foreign)
6:33am
6-K
kao4lv2q0uj
14 Jul 21
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft
6:19am
6-K
n718k0e7lv3p
13 Jul 21
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
6:22am
6-K
vvlvbso3 eg
12 Jul 21
HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering
10:19am
6-K
hu6fs
6 Jul 21
Current report (foreign)
6:24am
6-K
rq5og4cfjdwl8zj5cx3l
2 Jul 21
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
7:14am
6-K
7zkgbi
30 Jun 21
HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong
6:34am
6-K
9r4fudn hy8
29 Jun 21
Current report (foreign)
6:40am
6-K
2m6cr104tdjlc
24 Jun 21
Current report (foreign)
9:07am